USANA Health Sciences

USANA Health Sciences

USANA Health Sciences was founded in 1992 by Dr. Myron Wentz, a microbiologist and immunologist, with its headquarters in Salt Lake City, Utah. The company began as a developer of advanced nutritional supplements and has since grown into a vertically integrated manufacturer and marketer. It went public on the Nasdaq in 1996 and now trades on the NYSE under the ticker USNA. The underlying wealth generation stems from direct-selling operations rather than a single liquidity event, with the founder retaining significant equity and board influence. USANA's deployed capital centers on internal R&D and manufacturing infrastructure for its core product categories — vitamins, dietary supplements, and personal-care items. The company owns its production facilities in Salt Lake City, which handle formulation, testing, and packaging, rather than outsourcing to third-party manufacturers. This represents a direct capital-at-risk posture that institutional allocators might recognize as concentrated operational principal risk, distinct from diversified fund investing. Its geographic footprint spans Asia-Pacific, where it derives the majority of its revenue, alongside North America and limited European markets. As a public company, USANA's scale is measured by revenue and market capitalization rather than AUM. The firm reported $921 million in net sales for fiscal year 2023, with a market capitalization fluctuating around $1 billion. While not a family office, the Wentz family's ownership concentration and the founder's continued involvement through the Myron Wentz Foundation and related vehicles create a blurring of corporate treasury and family-office dynamics. In May 2024, the company announced a $50 million share repurchase authorization, signaling a corporate treasury approach to capital return common among tightly controlled public entities. Structurally, USANA differs from other asset managers because it does not seek external limited partners or manage third-party capital. Its balance sheet is the sole vehicle, and its investment function is indistinguishable from corporate strategy. The succession structure remains tied to the founding scientist-owner model, with Kevin Guest's long tenure as CEO providing operational continuity but the Wentz name remaining central to brand identity and shareholder control.